VRDN - Viridian Therapeutics Inc
IEX Last Trade
14.66
-0.340 -2.319%
Share volume: 919,460
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$15.00
-0.34
-2.27%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-15 | 2022-11-14 | 2023-03-09 | 2023-05-10 | 2023-08-08 | 2023-11-13 | 2024-02-27 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 169.814 M | 440.580 M | 435.091 M | 386.642 M | 351.467 M | 328.757 M | 490.424 M | 630.381 M | |
| Current Assets | 166.151 M | 437.355 M | 431.173 M | 382.602 M | 346.331 M | 323.839 M | 486.478 M | 626.818 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 4.251 M | 5.635 M | 6.521 M | 8.616 M | 11.938 M | 10.730 M | 9.006 M | 13.529 M | |
| Short Term Investments | 4.251 M | 5.635 M | 6.521 M | 8.616 M | 11.938 M | 10.730 M | 9.006 M | 13.529 M | |
| Total Receivables | 693.000 K | 398.000 K | 102.000 K | 128.000 K | 102.000 K | 102.000 K | 102.000 K | 102.000 K | |
| Current Cash | 161.207 M | 431.322 M | 424.550 M | 373.858 M | 334.291 M | 313.007 M | 477.370 M | 613.187 M | |
| Total Non-current Assets | 3.663 M | 3.225 M | 3.918 M | 4.040 M | 5.136 M | 4.918 M | 3.946 M | 3.563 M | |
| Property Plant Equipment | 749.000 K | 825.000 K | 1.326 M | 1.590 M | 1.882 M | 1.800 M | 1.672 M | 1.526 M | |
| Other Assets | 2.914 M | 2.400 M | 2.592 M | 2.450 M | 3.254 M | 3.118 M | 2.274 M | 2.037 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 169.814 M | 440.580 M | 435.091 M | 386.642 M | 351.467 M | 328.757 M | 490.424 M | 630.381 M | |
| Total liabilities | 27.916 M | 31.573 M | 40.027 M | 36.093 M | 35.610 M | 45.181 M | 48.402 M | 47.851 M | |
| Total current liabilities | 21.388 M | 25.214 M | 33.349 M | 29.588 M | 28.657 M | 23.247 M | 26.635 M | 26.127 M | |
| Accounts Payable | 4.061 M | 12.152 M | 14.234 M | 7.872 M | 4.133 M | 3.735 M | 2.239 M | 2.676 M | |
| Other liabilities | 1.943 M | 1.746 M | 2.033 M | 1.828 M | 2.244 M | 1.934 M | 1.562 M | 1.396 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 4.585 M | 4.613 M | 4.645 M | 4.677 M | 4.709 M | 20.000 M | 20.205 M | 20.328 M | |
| Other liabilities | 1.943 M | 1.746 M | 2.033 M | 1.828 M | 2.244 M | 1.934 M | 1.562 M | 1.396 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 141.898 M | 409.007 M | 395.064 M | 350.549 M | 315.857 M | 283.576 M | 442.022 M | 582.530 M | |
| Common stock | 27.762 M | 33.742 M | 40.719 M | 42.242 M | 43.253 M | 43.655 M | 49.872 M | 61.099 M | |
| Retained earnings | -413.484 M | -442.389 M | -488.174 M | -556.325 M | -611.388 M | -659.048 M | -725.908 M | -774.450 M |